Deprived social status is associated with decreased use of oral chemotherapy in patients with metastatic colorectal cancer: A retrospective cohort study on administrative databases in a French University Hospital-Reference-Cited by-同舟云学术

Deprived social status is associated with decreased use of oral chemotherapy in patients with metastatic colorectal cancer: A retrospective cohort study on administrative databases in a French University Hospital

Published:2021-11-12 Issue:6 Volume:9 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Gautier Gwendoline¹,Lucas Mélodie²³,Vermeulin Thomas³⁴⁵,Di Fiore Frederic¹⁴,Merle Veronique³⁶^ORCID

Affiliation:

1. Department of Hepatogastroenterology Rouen University HospitalUNIROUEN Rouen France

2. Department of Medical Information Le Havre Hospital Le Havre France

3. Dynamiques et Evènements des Soins et des Parcours Research Group Rouen University HospitalUNIROUEN Rouen France

4. CLCC H. BecquerelUnicancer Rouen France

5. LEDA‐LEGOSUniversité Paris‐Dauphine Paris France

6. Inserm U1086 ANTICIPE Caen France

Funder

Ministère des Affaires Sociales et de la Santé

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.888

Reference35 articles.

1. Plan Cancer 2014‐2019. 4 février 2014. Accessed July 24 2020.https://solidarites‐sante.gouv.fr/IMG/pdf/2014‐02‐03_Plan_cancer‐2.pdf

2. PhelipJ‐M.Thesaurus National de cancerologie digestive: cancer colorectal metastatique.2019. 75.

3. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

4. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

5. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer